ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo aims to extend lives in esophageal cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Microscopic clues to esophageal cancer spread revealed in new study
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at tissue samples from 30 people with esophageal squamous cell carcinoma to see how far the cancer spreads beyond what the surgeon can see. Researchers want to find patterns of hidden tumor growth to help guide future surgeries. Participants have already had thei…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Shanghai Chest Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
French study tracks Real-World success of combo therapy for stomach cancer
Knowledge-focused OngoingThis study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC